A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates

Zachary A. Bornholdt, Andrew S. Herbert, Chad Mire, Shihua He, Robert Cross, Anna Z. Wec, Dafna M. Abelson, Joan B. Geisbert, Rebekah M. James, Md Niaz Rahim, Wenjun Zhu, Viktoriya Borisevich, Logan Banadyga, Bronwyn M. Gunn, Krystle N. Agans, Ariel S. Wirchnianski, Eileen Goodwin, Kevin Tierney, William S. Shestowsky, Ognian Bohorov & 13 others Natasha Bohorova, Jesus Velasco, Eric Ailor, Do Kim, Michael H. Pauly, Kevin J. Whaley, Galit Alter, Laura M. Walker, Kartik Chandran, Larry Zeitlin, Xiangguo Qiu, Thomas Geisbert, John M. Dye

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Recent and ongoing outbreaks of Ebola virus disease (EVD) underscore the unpredictable nature of ebolavirus reemergence and the urgent need for antiviral treatments. Unfortunately, available experimental vaccines and immunotherapeutics are specific for a single member of the Ebolavirus genus, Ebola virus (EBOV), and ineffective against other ebolaviruses associated with EVD, including Sudan virus (SUDV) and Bundibugyo virus (BDBV). Here we show that MBP134AF, a pan-ebolavirus therapeutic comprising two broadly neutralizing human antibodies (bNAbs), affords unprecedented effectiveness and potency as a therapeutic countermeasure to antigenically diverse ebolaviruses. MBP134AF could fully protect ferrets against lethal EBOV, SUDV, and BDBV infection, and a single 25-mg/kg dose was sufficient to protect NHPs against all three viruses. The development of MBP134AF provides a successful model for the rapid discovery and translational advancement of immunotherapeutics targeting emerging infectious diseases.

Original languageEnglish (US)
Pages (from-to)49-58.e5
JournalCell Host and Microbe
Volume25
Issue number1
DOIs
StatePublished - Jan 9 2019

Fingerprint

Ebolavirus
Ferrets
Primates
Antibodies
Ebola Hemorrhagic Fever
Viruses
Therapeutics
Emerging Communicable Diseases
Sudan
Virus Diseases
Neutralizing Antibodies
Antiviral Agents
Disease Outbreaks
Vaccines

Keywords

  • ADI-15878
  • ADI-23774
  • BDBV
  • Bundibugyo
  • ebolavirus
  • EBOV
  • MBP134
  • pan-ebolavirus
  • Sudan
  • SUDV

ASJC Scopus subject areas

  • Parasitology
  • Microbiology
  • Virology

Cite this

A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates. / Bornholdt, Zachary A.; Herbert, Andrew S.; Mire, Chad; He, Shihua; Cross, Robert; Wec, Anna Z.; Abelson, Dafna M.; Geisbert, Joan B.; James, Rebekah M.; Rahim, Md Niaz; Zhu, Wenjun; Borisevich, Viktoriya; Banadyga, Logan; Gunn, Bronwyn M.; Agans, Krystle N.; Wirchnianski, Ariel S.; Goodwin, Eileen; Tierney, Kevin; Shestowsky, William S.; Bohorov, Ognian; Bohorova, Natasha; Velasco, Jesus; Ailor, Eric; Kim, Do; Pauly, Michael H.; Whaley, Kevin J.; Alter, Galit; Walker, Laura M.; Chandran, Kartik; Zeitlin, Larry; Qiu, Xiangguo; Geisbert, Thomas; Dye, John M.

In: Cell Host and Microbe, Vol. 25, No. 1, 09.01.2019, p. 49-58.e5.

Research output: Contribution to journalArticle

Bornholdt, ZA, Herbert, AS, Mire, C, He, S, Cross, R, Wec, AZ, Abelson, DM, Geisbert, JB, James, RM, Rahim, MN, Zhu, W, Borisevich, V, Banadyga, L, Gunn, BM, Agans, KN, Wirchnianski, AS, Goodwin, E, Tierney, K, Shestowsky, WS, Bohorov, O, Bohorova, N, Velasco, J, Ailor, E, Kim, D, Pauly, MH, Whaley, KJ, Alter, G, Walker, LM, Chandran, K, Zeitlin, L, Qiu, X, Geisbert, T & Dye, JM 2019, 'A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates', Cell Host and Microbe, vol. 25, no. 1, pp. 49-58.e5. https://doi.org/10.1016/j.chom.2018.12.005
Bornholdt, Zachary A. ; Herbert, Andrew S. ; Mire, Chad ; He, Shihua ; Cross, Robert ; Wec, Anna Z. ; Abelson, Dafna M. ; Geisbert, Joan B. ; James, Rebekah M. ; Rahim, Md Niaz ; Zhu, Wenjun ; Borisevich, Viktoriya ; Banadyga, Logan ; Gunn, Bronwyn M. ; Agans, Krystle N. ; Wirchnianski, Ariel S. ; Goodwin, Eileen ; Tierney, Kevin ; Shestowsky, William S. ; Bohorov, Ognian ; Bohorova, Natasha ; Velasco, Jesus ; Ailor, Eric ; Kim, Do ; Pauly, Michael H. ; Whaley, Kevin J. ; Alter, Galit ; Walker, Laura M. ; Chandran, Kartik ; Zeitlin, Larry ; Qiu, Xiangguo ; Geisbert, Thomas ; Dye, John M. / A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates. In: Cell Host and Microbe. 2019 ; Vol. 25, No. 1. pp. 49-58.e5.
@article{1a8ad9b4fb5245be994b46fef9ab9180,
title = "A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates",
abstract = "Recent and ongoing outbreaks of Ebola virus disease (EVD) underscore the unpredictable nature of ebolavirus reemergence and the urgent need for antiviral treatments. Unfortunately, available experimental vaccines and immunotherapeutics are specific for a single member of the Ebolavirus genus, Ebola virus (EBOV), and ineffective against other ebolaviruses associated with EVD, including Sudan virus (SUDV) and Bundibugyo virus (BDBV). Here we show that MBP134AF, a pan-ebolavirus therapeutic comprising two broadly neutralizing human antibodies (bNAbs), affords unprecedented effectiveness and potency as a therapeutic countermeasure to antigenically diverse ebolaviruses. MBP134AF could fully protect ferrets against lethal EBOV, SUDV, and BDBV infection, and a single 25-mg/kg dose was sufficient to protect NHPs against all three viruses. The development of MBP134AF provides a successful model for the rapid discovery and translational advancement of immunotherapeutics targeting emerging infectious diseases.",
keywords = "ADI-15878, ADI-23774, BDBV, Bundibugyo, ebolavirus, EBOV, MBP134, pan-ebolavirus, Sudan, SUDV",
author = "Bornholdt, {Zachary A.} and Herbert, {Andrew S.} and Chad Mire and Shihua He and Robert Cross and Wec, {Anna Z.} and Abelson, {Dafna M.} and Geisbert, {Joan B.} and James, {Rebekah M.} and Rahim, {Md Niaz} and Wenjun Zhu and Viktoriya Borisevich and Logan Banadyga and Gunn, {Bronwyn M.} and Agans, {Krystle N.} and Wirchnianski, {Ariel S.} and Eileen Goodwin and Kevin Tierney and Shestowsky, {William S.} and Ognian Bohorov and Natasha Bohorova and Jesus Velasco and Eric Ailor and Do Kim and Pauly, {Michael H.} and Whaley, {Kevin J.} and Galit Alter and Walker, {Laura M.} and Kartik Chandran and Larry Zeitlin and Xiangguo Qiu and Thomas Geisbert and Dye, {John M.}",
year = "2019",
month = "1",
day = "9",
doi = "10.1016/j.chom.2018.12.005",
language = "English (US)",
volume = "25",
pages = "49--58.e5",
journal = "Cell Host and Microbe",
issn = "1931-3128",
publisher = "Cell Press",
number = "1",

}

TY - JOUR

T1 - A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates

AU - Bornholdt, Zachary A.

AU - Herbert, Andrew S.

AU - Mire, Chad

AU - He, Shihua

AU - Cross, Robert

AU - Wec, Anna Z.

AU - Abelson, Dafna M.

AU - Geisbert, Joan B.

AU - James, Rebekah M.

AU - Rahim, Md Niaz

AU - Zhu, Wenjun

AU - Borisevich, Viktoriya

AU - Banadyga, Logan

AU - Gunn, Bronwyn M.

AU - Agans, Krystle N.

AU - Wirchnianski, Ariel S.

AU - Goodwin, Eileen

AU - Tierney, Kevin

AU - Shestowsky, William S.

AU - Bohorov, Ognian

AU - Bohorova, Natasha

AU - Velasco, Jesus

AU - Ailor, Eric

AU - Kim, Do

AU - Pauly, Michael H.

AU - Whaley, Kevin J.

AU - Alter, Galit

AU - Walker, Laura M.

AU - Chandran, Kartik

AU - Zeitlin, Larry

AU - Qiu, Xiangguo

AU - Geisbert, Thomas

AU - Dye, John M.

PY - 2019/1/9

Y1 - 2019/1/9

N2 - Recent and ongoing outbreaks of Ebola virus disease (EVD) underscore the unpredictable nature of ebolavirus reemergence and the urgent need for antiviral treatments. Unfortunately, available experimental vaccines and immunotherapeutics are specific for a single member of the Ebolavirus genus, Ebola virus (EBOV), and ineffective against other ebolaviruses associated with EVD, including Sudan virus (SUDV) and Bundibugyo virus (BDBV). Here we show that MBP134AF, a pan-ebolavirus therapeutic comprising two broadly neutralizing human antibodies (bNAbs), affords unprecedented effectiveness and potency as a therapeutic countermeasure to antigenically diverse ebolaviruses. MBP134AF could fully protect ferrets against lethal EBOV, SUDV, and BDBV infection, and a single 25-mg/kg dose was sufficient to protect NHPs against all three viruses. The development of MBP134AF provides a successful model for the rapid discovery and translational advancement of immunotherapeutics targeting emerging infectious diseases.

AB - Recent and ongoing outbreaks of Ebola virus disease (EVD) underscore the unpredictable nature of ebolavirus reemergence and the urgent need for antiviral treatments. Unfortunately, available experimental vaccines and immunotherapeutics are specific for a single member of the Ebolavirus genus, Ebola virus (EBOV), and ineffective against other ebolaviruses associated with EVD, including Sudan virus (SUDV) and Bundibugyo virus (BDBV). Here we show that MBP134AF, a pan-ebolavirus therapeutic comprising two broadly neutralizing human antibodies (bNAbs), affords unprecedented effectiveness and potency as a therapeutic countermeasure to antigenically diverse ebolaviruses. MBP134AF could fully protect ferrets against lethal EBOV, SUDV, and BDBV infection, and a single 25-mg/kg dose was sufficient to protect NHPs against all three viruses. The development of MBP134AF provides a successful model for the rapid discovery and translational advancement of immunotherapeutics targeting emerging infectious diseases.

KW - ADI-15878

KW - ADI-23774

KW - BDBV

KW - Bundibugyo

KW - ebolavirus

KW - EBOV

KW - MBP134

KW - pan-ebolavirus

KW - Sudan

KW - SUDV

UR - http://www.scopus.com/inward/record.url?scp=85058702898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058702898&partnerID=8YFLogxK

U2 - 10.1016/j.chom.2018.12.005

DO - 10.1016/j.chom.2018.12.005

M3 - Article

VL - 25

SP - 49-58.e5

JO - Cell Host and Microbe

JF - Cell Host and Microbe

SN - 1931-3128

IS - 1

ER -